Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
https://www.curevac.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 999
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Alexander Zehnder M.B.A., M.D. | CEO, MD & Member of Management Board | 1,05M | S.O. | 1970 |
Mr. Pierre Kemula B.Sc. | MD, CFO & Member of Management Board | 704,35k | S.O. | 1975 |
Dr. Malte Greune Ph.D. | COO, Member of Management Board & MD | 646,81k | S.O. | 1965 |
Dr. Myriam Mendila M.D. | Chief Development Officer, MD & Member of the Management Board | 661,62k | S.O. | 1966 |
Dr. Ulrike Gnad-Vogt M.D., Ph.D. | Senior VP & Area Head of Oncology | 305,94k | S.O. | 1973 |
Dr. Sarah Fakih | Vice President Corporate Communications & Investor Relations | S.O. | S.O. | S.O. |
Mr. Marco Rau L.L.M., Ph.D. | General Counsel | S.O. | S.O. | S.O. |
Mr. Thorsten Schuller | Head of Corporate Communications | S.O. | S.O. | S.O. |
Slavica Stevanovic-Heck | Head of Human Resources | S.O. | S.O. | S.O. |
Dr. Patrick Baumhof | Senior Vice President of Technology | S.O. | S.O. | S.O. |
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
L’ISS Governance QualityScore de CureVac N.V. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..